The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients

Korean Journal of Urology

Volumn 48, Issue 8, 2007, Pages 858-862

  Ryu, Young Guen ^a   Kim, Hyung Jee ^a   Park, Heung Jae ^b  

^a Dankook University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Alpha blocker; Pain; Prostate

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TOSUFLOXACIN;

ADULT; ARTICLE; CHRONIC PROSTATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; PELVIS PAIN SYNDROME; QUALITY OF LIFE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SYMPTOM;

EID: 34548314336     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.8.858     Document Type: Article

References (22)

1. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-8
2. Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167:1363-6
3. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, et al. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol 2002;168:593-8
4. McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001;16:656-62
5. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7
6. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 1999;54:229-33
7. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, et al. Chronic Prostatitis Collaborative Research Network. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581-9
8. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 2004;64:881-6
9. Collins MM, O'Leary MP, Barry MI. Prevalence of bother-some genitourinary symptoms and diagnoses in younger men on routine primary care visits. Urology 1998;52:422-7
10. Ku JH, Kim ME, Lee NK, Park YH. The prevalence of chronic prostatitis-like symptoms in young men: a community-based survey. Urol Res 2001;29:108-12
11. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intraprostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-31
12. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/ chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171:1594-7
13. Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom. PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 2003;62:425-9
14. de la Rosette JJ, Karthaus HF, van Kerrebroeck PE, de Boo T, Debruyne FM. Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. Eur Urol 1992;22:222-7
15. Lacquaniti S, Destito A, Servello C, Candidi MO, Weir JM, Brisinda G, et al. Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl 1999;71:283-5
16. Lee JH, Jeon JS, Cho IR. Characteristic symptoms of chronic prostatitis/ chronic pelvic pain syndrome. Korean J Urot 2002; 43:852-7
17. Litwin MS. A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002;60:14-8
18. Zhang JG, Wang YL, Ren XQ, Gao ZW, Cheng YH. Sexual function of men with symptomatic benign prostatic hyperplasia and effect of tamsulosin. Zhonghua Nan Ke Xue 2006;12:723-5
19. Lee SW, Liong ML, Yuen KH, Liong YV, Krieger IN. Chronic prostatitis/ chrome pelvic pain syndrome: role of alpha blocker therapy. Urol Int 2007;78:97-105
20. Jung YH, Kim JG, Cho IR. The efficacy of terazosin in the management of chronic pelvic pain syndrome (CPPS): comparison between category IIIa and IIIb. Korean J Urol 2006; 47:1191-6
21. Schaeffer AJ. National Institute of Diabetes and Digestive and Kidney Diseases of the US National Institutes of Health. NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelmes for bacterial prostatitis. Int J Antimicrob Agents 2004;24(Suppl 1):S49-52
22. Fall M, Baranowski AP, Fowler CJ, Lepinard V, Malone-Lee JG, Messelink EJ, et al. EAU guidelines on chronic pelvic pain. Eur Urol 2004;46:681-9